Inventor · disambiguated record
Christopher Chiu
Also filed as: CHIU CHRISTOPHER · CHIU CHRISTOPHER W L
8 granted patents·11 pending applications·160 citations·filing 2015–2023
87Inventor score
Top patents by PatentIndex Score
19 records- 0196US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 0296US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 0395US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 0495US9686296B1Systems and methods for providing network security monitoringBLACKPOINT HOLDINGS LLC·Filed 2015·Granted Jun 20, 2017·121 cites·25 claims
- 0593US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 0691US11618787B2Methods of treating high risk multiple myelomaJANSSEN BIOTECH INC·Filed 2018·Granted Apr 4, 2023·10 cites·12 claims
- 0778US12435154B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2021·Granted Oct 7, 2025·1 cites·29 claims
- 0878US10057234B1Systems and methods for providing network security monitoringBLACKPOINT HOLDINGS LLC·Filed 2017·Granted Aug 21, 2018·3 cites·20 claims
- 0978US2024301078A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1068US2023340145A1Methods of Treating High Risk Multiple MyelomaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1168US2024034812A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1267US2025101102A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1367US2025115665A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1467US2023241211A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1567US2023303693A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1663US2025304689A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2023·Application pending·0 cites
- 1763US2023312758A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1863US2023357440A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1961US2023312757A1Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher Chiu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →